Preannouncement TRANSCAN-3 JTC 2024: "Combination therapies against cancer: new opportunities for translational research"

Calls
08/04/2024
Preannouncement TRANSCAN-3 JTC 2024: "Combination therapies against cancer: new opportunities for translational research"
08/04/2024
05/07/2024
European Commission
Projects
International
08/04/2024
Añadir al calendario 2024-04-08 02:00:00 2024-07-05 02:00:00 Preannouncement TRANSCAN-3 JTC 2024: "Combination therapies against cancer: new opportunities for translational research" The call is planned to be launched on April 26th 2024 with a submission deadline for pre-proposals in July 05th, 2024. It is expected that consortia invited to the full-proposal stage will be asked to submit their proposal in November 29th, 2024. The main purpose of this call will be design of patient preclinical models for combination therapies. Translational research using tumour samples collected from retrospective and/or prospective cohorts of patients. Projects should be built from a solid and established hypothesis and should be relevant regarding the potential improvements in clinical practice. Aims: Development of new tumour derived models to test new drug combination therapies Design and development of high-throughput drug combination screening platforms to test new combination therapies Use of immunotherapy and radiotherapy combinations strategies to overcome drug resistance More info through this link.  Location Navarrabiomed info@navarrabiomed Europe/Madrid public

The call is planned to be launched on April 26th 2024 with a submission deadline for pre-proposals in July 05th, 2024. It is expected that consortia invited to the full-proposal stage will be asked to submit their proposal in November 29th, 2024.

The main purpose of this call will be design of patient preclinical models for combination therapies. Translational research using tumour samples collected from retrospective and/or prospective cohorts of patients. Projects should be built from a solid and established hypothesis and should be relevant regarding the potential improvements in clinical practice. Aims:

  1. Development of new tumour derived models to test new drug combination therapies
  2. Design and development of high-throughput drug combination screening platforms to test new combination therapies
  3. Use of immunotherapy and radiotherapy combinations strategies to overcome drug resistance

More info through this link